The abstract is read at the publisher; the summary is JClub's.
In community-dwelling Australian adults aged 70+ without cardiovascular disease, atorvastatin 40 mg daily reduced major cardiovascular events (HR 0.70) after a median 5.9 years.
- Why it matters: The benefit and safety of statins for primary prevention in older adults, especially for extending disability-free survival, is uncertain.
- What they did: In a double-blind randomized placebo-controlled trial (n=9971), participants received atorvastatin 40 mg once daily or placebo, with hierarchical testing of two composite primary endpoints.
- The result: Disability-free survival was not improved: death from any cause, dementia, or persistent physical disability occurred in 21.6 vs 23.0 events per 1000 person-years (HR 0.94; P=0.25).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.